Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

Not available.

[1]  P. Sonneveld,et al.  Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.

[2]  P. Sonneveld,et al.  Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Nanni,et al.  Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials , 2020, Cancers.

[4]  P. Sonneveld,et al.  Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study , 2019, The Lancet.

[5]  C. Nanni,et al.  Interest of Pet Imaging in Multiple Myeloma , 2019, Front. Med..

[6]  Hiroki Kobayashi,et al.  Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  M. Kumar,et al.  The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. , 2018, Blood.

[8]  O. Stephens,et al.  Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing , 2017, Nature Communications.

[9]  Jean-Michel Nguyen,et al.  Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Caleb K. Stein,et al.  Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. , 2017, Blood.

[11]  Bart Barlogie,et al.  Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. , 2017, The Lancet. Oncology.

[12]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[13]  C. Nanni,et al.  Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  R. Fanin,et al.  Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. , 2011, Blood.

[15]  B. Barlogie,et al.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.